GlassScriptPhysician profile
Ghanem Sharabi
NPI 1508874504
$4,917.36
in general payments reported to CMS, 2019-2025
40 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $418 · 2021: $805 · 2022: $743 · 2023: $700 · 2024: $736 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $826.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $721.50 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $692.07 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $387.60 | 2021-2025 | Vraylar |
| Abbott Laboratories | $233.09 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.73 | 2021-2025 | Jardiance, Jascayd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.56 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $153.20 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $130.41 | 2019-2022 | |
| Amarin Pharma, INC. | $129.46 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $124.71 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $113.67 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $89.20 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.59 | 2021-2024 | Eliquis |
| Mylan Specialty L.P. | $77.86 | 2023-2024 | Yupelri |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.36 | 2019-2025 | Kisunla, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $69.09 | 2022 | |
| Pfizer INC. | $57.65 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $55.30 | 2020-2024 | |
| Exact Sciences Corporation | $55.06 | 2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $52.11 | 2024 | Opsumit, Uptravi |
| Acadia Pharmaceuticals INC | $36.29 | 2020-2022 | |
| Inspire Medical Systems, INC. | $33.16 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $27.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.46 | 2024 | Crysvita |
| Nestle Healthcare Nutrition INC. | $23.71 | 2021 | |
| Viatris Specialty LLC | $23.17 | 2025 | Yupelri |
| Insulet Corporation | $22.90 | 2023 | Omnipod |
| Viiv Healthcare Company | $21.93 | 2025 | Dovato |
| Lundbeck LLC | $21.62 | 2023 | Rexulti |
| Ucb, INC. | $19.23 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.72 | 2023 | Givlaari |
| Urovant Sciences INC | $18.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.90 | 2024 | Rexulti |
| Inogen, INC. | $16.35 | 2023 | Inogen |
| Xeris Pharmaceuticals, INC. | $16.31 | 2024 | Gvoke Hypopen |
| Inari Medical, INC. | $15.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceuticals, INC. | $15.47 | 2021 | |
| Glaxosmithkline, LLC. | $13.84 | 2023 | Trelegy Ellipta |
| Zyla Life Sciences, INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghanem Sharabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.